TXG

10X Genomics Inc

Add to Watchlist

Advanced Chart

12.290

-0.51(-3.984%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

14.490

Open

14.490

VWAP

12.30

Vol

4.79M

Mkt Cap

2.38B

Low

11.880

Amount

58.95M

EV/EBITDA(TTM)

Total Shares

119.71M

873.39M

EV/OCF(TTM)

15.39

P/S(TTM)

2.05

10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for single cell and spatial biology systems. Its single cell portfolio, powered by Chromium platform, includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Visium Spatial Gene Expression, and others.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q3

FY2025Q4

139.41M

-8.95%

143.60M

-5.31%

155.21M

-5.94%

Estimates Revision

The market is revising No Change the revenue expectations for 10x Genomics, Inc. (TXG) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 29.50%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+29.50%

In Past 3 Month

10 Analyst Rating

5.78% Upside

Wall Street analysts forecast TXG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TXG is 13.00 USD with a low forecast of 9.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

6 Hold

0 Sell

Moderate Buy

5.78% Upside

Current: 12.290

Low

9.00

Averages

13.00

High

18.00

5.78% Upside

Current: 12.290

Low

9.00

Averages

13.00

High

18.00

Barclays

Overweight

maintain

$13 -> $15

2025-08-08

New

Reason

Barclays

Price Target

$13 -> $15

2025-08-08

New

maintain

Overweight

Reason

Barclays raised the firm's price target on 10x Genomics to $15 from $13 and keeps an Overweight rating on the shares post the earnings report. The firm says the integration of Scale's split-pool barcoding with Chromium's droplet-based technology could give 10x "the best of both worlds."

Deutsche Bank

Justin Bowers

Hold

maintain

$10 -> $14

2025-08-08

New

Reason

Deutsche Bank

Justin Bowers

Price Target

$10 -> $14

2025-08-08

New

maintain

Hold

Reason

Deutsche Bank analyst Justin Bowers raised the firm's price target on 10x Genomics to $14 from $10 and keeps a Hold rating on the shares.

UBS

Dan Leonard

Neutral

maintain

$12 -> $13

2025-08-08

New

Reason

UBS

Dan Leonard

Price Target

$12 -> $13

2025-08-08

New

maintain

Neutral

Reason

UBS analyst Dan Leonard raised the firm's price target on 10x Genomics to $13 from $12 and keeps a Neutral rating on the shares. While 10x Genomics reported a quarterly beat, the muted environment is here to stay, the analyst tells investors in a research note.

BofA

Michael Ryskin

Neutral

maintain

$12 -> $13

2025-06-26

Reason

BofA

Michael Ryskin

Price Target

$12 -> $13

2025-06-26

maintain

Neutral

Reason

BofA analyst Michael Ryskin raised the firm's price target on 10x Genomics to $13 from $12 and keeps a Neutral rating on the shares. The firm is updating its price targets for stocks under its coverage in the Life Sciences & Diagnostic Tools, LSTs, sector, the analyst tells investors. The firm notes LSTs remain under pressure as uncertainty persists with the macro environment and U.S. government policies. Recent weeks, however, have seen some signs of improvement as tariff concerns have cools slightly, the firm adds.

Barclays

Overweight

maintain

$12 -> $13

2025-06-24

Reason

Barclays

Price Target

$12 -> $13

2025-06-24

maintain

Overweight

Reason

Barclays raised the firm's price target on 10x Genomics to $13 from $12 and keeps an Overweight rating on the shares as part of a Q2 preview for the life science and diagnostic tools sector. Sentiment on the group is shifting more positive on the notion that many of the unknown headwinds around policy changes, namely National Institutes of Health budgetary cuts and pharma tariffs, are likely to prove less severe than feared, the analyst tells investors in a research note. Barclays still favors businesses exposed to commercial and clinical volumes, mainly bioprocessing and diagnostics.

UBS

Neutral

downgrade

$14 -> $12

2025-05-13

Reason

UBS

Price Target

$14 -> $12

2025-05-13

downgrade

Neutral

Reason

UBS lowered the firm's price target on 10x Genomics to $12 from $14 and keeps a Neutral rating on the shares. The firm updated its forecast to reflect ongoing pressures in academic funding, the analyst tells investors in a research note.

See All Ratings

Valuation Metrics

The current forward P/E ratio for 10X Genomics Inc (TXG.O) is -8.62, compared to its 5-year average forward P/E of -112.82. For a more detailed relative valuation and DCF analysis to assess 10X Genomics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-112.82

Current PE

-8.62

Overvalued PE

30.52

Undervalued PE

-256.15

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-537.11

Current EV/EBITDA

-7.40

Overvalued EV/EBITDA

1229.50

Undervalued EV/EBITDA

-2303.73

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued

5Y Average PS

14.97

Current PS

2.13

Overvalued PS

27.64

Undervalued PS

2.31